Project Details
Description
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, with a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects with Moderate-to-Severe Alopecia Areata
| Status | Active |
|---|---|
| Effective start/end date | 5/14/20 → 5/31/25 |
Funding
- ARENA PHARMACEUTICALS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.